RecruitingPhase 3NCT06668181

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Sponsor

UCB Biopharma SRL

Enrollment

40 participants

Start Date

Mar 11, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Eligibility

Min Age: 2 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bimekizumab for people with enthesitis related arthritis and juvenile psoriatic arthritis. The study is currently recruiting participants at 23 locations. People eligible for this study include aged 2 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBimekizumab

Bimekizumab will be administered at pre-specified timepoints.

Locations(23)

Ja0005 50646

Calgary, Canada

Ja0005 50644

Montreal, Canada

Ja0005 50645

Saskatoon, Canada

Ja0005 40777

Indre-et-Loire, France

Ja0005 40510

Le Kremlin-Bicêtre, France

Ja0005 40778

Paris, France

Ja0005 40776

Poitiers, France

Ja0005 40369

Berlin, Germany

Ja0005 40356

Dresden, Germany

Ja0005 40072

Freiburg im Breisgau, Germany

Ja0005 40852

Hamburg, Germany

Ja0005 40787

Sankt Augustin, Germany

Ja0005 40779

Sendenhorst, Germany

Ja0005 40427

Tübingen, Germany

Ja0005 40720

Krakow, Poland

Ja0005 40780

Sosnowiec, Poland

Ja0005 40781

Esplugues de Llobregat, Spain

Ja0005 40100

Madrid, Spain

Ja0005 40782

Valencia, Spain

Ja0005 40786

Bristol, United Kingdom

Ja0005 40783

Manchester, United Kingdom

Ja0005 40785

Nottingham, United Kingdom

Ja0005 40784

Stroke-on-trent, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06668181

Related Trials

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

NCT067512388 locations

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT0610074434 locations

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT0686955147 locations

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

NCT057670477 locations

The Reliability and Validity of the Ankylosing Spondylitis Performance Index (ASPI) in Enthesitis-Related Arthritis

NCT063831951 location